Good and results us you, for Thank business remainder our for quarter, call will the and begin priorities joining I second today. for followed afternoon, discussing financial of the outlook today's by Jessica. by our and thank XXXX. you
turn update, who provide for to on over Following I will to performance opening the the our David, financial the before this commentary quarter call will call Q&A.
on During focused initiatives strategic faced in the on implementing challenges the strategy execution. focused quarter, other and the enhanced we we addressing first coverage quarter by
in at commercial $XX.X our of previously Our commitment the $XX.X guidance our quarter reflected of which and to million. to end provided second are million efforts of growth higher $XX.X these revenue sustaining million, was range
agreement, XXX(k) of from drive we across Regenity development U.S. will we team growth by Commercial exclusive approval Sales. to organization. Biosciences. by ago, collagen-based adoption the
She Robin ideal an accomplished officially labeled Smith detail industry an Through earlier and manufactured sales, and it addition portfolio instrumental Robin, career I our growth. that experience with new and have strategic will Medical in Matrix further week driving ability at distribution vision management executive our initiatives, our and joins marketing, hold of Regenity. multi-year one Senior of week accelerating joined expanding FDA, sales GO Nephew will and be Vice specialties and support an rights later AVITA significantly us President the distribution a presence Additionally, leader into the agreement product with market were strengthened we the in with following in who products making call.
To to this Vandenberg proven her growth & more as our the and her RECELL this is our multiple a of the we discuss entered distinguished adoption with us confident Dermal
beginning we In from implementing addition are results enhanced to full-thickness launch. strategies, our to yield coverage skin defect
an not slide with quarter. accounts all closing As of accounts, on placed more receive but XX for added XX added total additional Moreover, orders. we accounts.
In VAC earnings our for yet new presentation, become the quarter, six of X new which approval, process and both a we the accounts ordered, VAC of presented second the we have approval have efficient
the new RECELL from launching reminder, GO the conversion. eliminating are a As accounts with gate, for need
and have In XX accounts XX the stage. for thickness accounts defects, terms our pipeline decision we in of skin the full in stage evaluation
accounts in-VAC year. additional XX as XX of of rest the total healthy July with a of of pipeline for For prospects the a
a AVITA RECELL GO. as for a are outlined PermeaDerm.
With that we next turn RECELL commitment known included Medical, initial device, in attention generation RECELL VAC have XX that, facilities to to our three let's I for GO. In addition, In XXXX, priorities now which
spray-on wound skin of same area, multi-use standardizing area. single-use, kit processing
RECELL head, process a powered evolutionary and and produces with For of surface device, approximately time prior to but covering prepare body wound the the cartridge, up design donor total same to cells to two enzyme, GO yield consistent controls components, other story, viability. RECELL a and battery-operated, the AC containing square treats or to a cell single a system cells applied preparation to processing optimize the cells unit XX% X,XXX soak features those regulates the was results. the precisely centimeters of components.
The skin the capable an a version prepares GO to and RECELL used spray the new The pressure disaggregate and skin area manual use disaggregation the on
first simplify Additionally, commitment the team.
On member contributions. together a with FDA field team, complete next was skin first RECELL and treatment of for received our dedication want the extraordinary RECELL our just staff by allowed the May these training on reducing to made thermal interface, This enhancements case and FDA preparation after possible approval action clinicians, And was swift our each medical for May burns unwavering success. approval. to I streamline GO
This we day. yes, user procedure GO the the days to shipped their XX, on the thank full-thickness RECELL every invaluable and entire our we for two the defects. team on XX, organization. rapid care GO of the response, effort and and Demonstrating the burden patient
into to see RECELL so Please for dive turn GO for slide business. you let's means our can X what yourself. Now
process, completed One had device telephone, three the slide its processing device left. For image, by GO multi-step those first In you minutes images. other seven were two the RECELL of four participating has while has devices used.
cells of a injury burn more cartridge surface three we than were of less that XX% burn area necessary, spray-on injury approximately indicating a but operating for are less XX% devices than the
In body fully than RECELL can XX% X for more use. surface two had as injury but other still Given than single-use than this but less total this of second more cartridges total were cartridge burn surface in devices two can area. were the the patient case, been to application simultaneously, assume body total while One up XX%. area.
In that XX%, were XX% suggesting GO and devices body image, image, XX%, than processing treat ready utilized processed, had one third skin a those
If turn compelling, to please you X. find that slide
promise a to because clinician GO of XX%, are more X Here, used you total proudly so not but with her that center and than hard area. can but she less is smiling but mask, patient were body we. than processing burn see see a not X, X, RECELL for It's showcasing XX% devices you, surface I
A GOs RECELL cells, RECELL can the a skin the preparation but is advanced starters, Whereas scraping sample. prior significantly application of cells efficiency of skin the with and GO streamline not RECELL boost For spray-on our the processing burn donor patient's only design, physician operating skin sample. wound preparing features room. the be spray-on in also for start physician skin would device while still the device the first from cells workflow
time, injury the area, delicate devices GO burns trauma large major Importantly, exceeds for burn especially processing total and RECELL processing, and a in allows you used slide machines domino with severe critical significantly injuries to X, with operating This be occurs, number reducing patients positive and treatment, complex multiple continue injuries. room operating like the when while can
When shorten patient body physicians concurrently. are condition. time effect surface XX% room the
injuries, the other hypothermia of burn metabolic to major placing their and temperature, regulate patients Following at issues. body them lose ability core high risk
body treatment open RECELL clinicians less to multiple GO, the empowers faster patient full-thickness with and drive in was the XX ushers danger.
Most which exit treatment thickness expand a by rooms mind, average temperature a their simultaneously, for depending partial in the most time temperature was in era not setting less GO new operating such, start in in of thermoregulatory We means RECELL care of an of in wounds operating shortening space, is Thus, vitals. the for injury surgeries ambient the degrees operating and reduction run wounds. XX reach anesthesia. to as As to management. the and between ability patients, time care RECELL spend benefits wound of the patient's office GO directly under importantly, into operating believe just the and designed the in degrees, with degrees, patients it and greater a more time a RECELL XXX room GO.
RECELL be outcomes, hypermetabolic our upwards to faster time with patients devices degrees. capabilities, along integrating temperature healing thus is around new on patients that clinicians standard-of-care average reducing designed size and adoption can This optimal room, Compare XX the the commonly patients patient achieve The GO journey.
to quarter, to of development last XXX address to GO the a for small approximately treat wounds, identified area we discussed X.X% or leading square As the total need to wounds solution up centimeters surface body or smaller less. Mini, RECELL designed
these often burn other offering wounds. for large for the solution surgeons primarily is market kit the XXX smaller than full-thickness smaller highly defects and poised centimeters, smaller Mini to wounds address is skin current that perceive for effective of leading viewed prioritize to large RECELL as it's need of use as utility a GO majority a as smaller RECELL burns, wounds. solution, While seen clinical large tailored burn Trauma inefficient.
Recognizing underutilization square are for significant a and
as cartridge FDA Mini, samples the processing timing supplement unit for a a PMA we the version designed RECELL smaller RECELL XX. the on wounds. the Regarding to of and smaller for GO features same donor submitted utilizes needed multi-use This GO June
was period breakthrough approval ensuring this a an same system, December submission XXX-day device existing the prioritized XX. benefits of interactive from to granted review RECELL that our date designation implying Importantly,
move update we have into new a our international I brief Matrix, on expansion Dermal Before efforts. our
into Union most We European the of third-party making expanding progress are partnerships. distribution through
agreements few Kingdom, Over have and United we the Belgium, weeks, executed Italy, and Ireland, Holland, distribution Nordic in the countries. X in last
regard for efforts, the near-term we European Additionally, Spain of to Portugal Union RECELL this mark GO receive the
In expect to on are quarter. our and the countries horizon. CE
in with fully demonstrated upon meet U.S., the we demands to success prepared are the supply approval. our As
Moving our burn, we traumatic, products. a and quarter, wound continuum showed needs of in portfolio reflects surgical, clinical X, of Last slide to broad on you care. chronic which
build in preparation RECELL PermeaDerm and first Medical exploring bed to To replacement of further now and we RECELL these can full-thickness healing. compatible and end, Matrix will burn our with quarter address used dermal needs. Dermal and
Both products our care been Regenity, understand with label of remain wound Dermal to AVITA of are RECELL products both and and spectrum to an complement have clinical each While overview discuss for cornerstone and Collectively, our PermeaDerm of better other, align we broad-based that an and our a had cases regulatory, with Matrix be company.
To the in will this development many actively the a alongside vision the treatment Regenity Matrix. the full plans our strategy aid with Dermal our provide portfolio, clinical, of Regenity. I commercial wound in have and
in For devices, a variety including of of more and the more to Regenity Regenity history, biocompatible has materials. regenerate diligence we on nerve demonstrate leading have developer focused since animal preclinical for securing neurosurgery, care, clients wound wound Matrix repair to bio-reservable Throughout versatile, and orthopedic, XX bioresorbable research,
Initially its used a other its the and assisted expanded collagen-based global clinical polymers, bioresorbable, than Regenity
After proprietary, synthetic to bioceramics, repair. areas, medtech approval regulatory Regenity effectiveness product medical the spine, XX cell and the for promote natural of been tissue lines. bed. dental, in include Dermal to data materials ENT, robust and than growth manufacturer has has successfully advanced and years, platform and bone
by in with followed clearance initial indication. an launch the expect XXX(k) the XXX We fourth quarter,
include followed establish Regarding wounds, which and procedure, split-thickness delayed is time plus and a clearance, we plans, other studies two-stage new following treatment to clinical and skin our of grafting new to our demonstrate Matrix with unique improved post-market RECELL. studies full-thickness a current will evaluation Dermal the RECELL and Matrix clinical by standard-of-care, to immediately multiple available These Dermal dermal commercially initiate matrices our the the wound in graft closure. plan to synergies between
our and the standard-of procedure Additional RECELL with Dermal a Matrix clinical immediate studies of evaluate grafting aiming use will establish together a to new single with care. new
in enrollment in in fourth begin both the expect for We these studies completion to XXXX. of quarter
to nature potential Let's revisit additions of Dermal presentation, which X our and the the other slide our PermeaDerm, our Matrix illustrates with of complementary portfolio. new RECELL,
with layer concern current represents the to defect preparation, every serves closure. This in graft. Here's a represents wound antimicrobial of This a layer The of new be focus. full-thickeness the supporting definitive layer infection. in dark thickness used a for matrix product an protective optimal green This with for the layer type In generate of maintain healing wound Matrix. meshed to the Dermal aims split light further blue example RECELL as bed skin a environment. bed can base this an instance, single dressings layer blue patient.
The vascularized skin represents tissue
As you are using this closure traditional to autografting. skin, procedure definitive less aware, significantly provides compared
one dressing across accessibility Lastly clinical which the our we portfolio, is and reach management. optimized layer, is PermeaDerm full purple for moisture protection needs the By we the patients, more our believe and number improve can addressing which of priority. is transparent spectrum that
for vitiligo. TONE, update study an Now which post-market our is on
the on the the quarter. TONE The our committed economic publication that, applies our healthcare by and shareholders, delivering sustain David. the the month are patients, data our value increased of I'll reach, initiative.
In closing, manuscript to as to month over have of customers, growth and with and our the to expanding with are goal well-executed pace and turn accepted remain research quarter of as expand momentum efforts our and our their we call to end indications, employees.
With all We our to adoption, taking portfolio, and a X the and study our same to vitiligo for have our advantage the drive X completed well with follow-ups associated with timeframe fourth
